ERBB3 and cancer: Conversely, HER3-targeted ADCs offer a novel approach to cancer treatment and have the potential to be a unique, effective therapeutic option for patients with metastatic breast cancer by lowering drug resistance, enhancing treatment efficacy, and minimizing systemic toxicity.